CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Cepentil

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionFeb 12, 2026
Entity authorityQ132069102 ↗
Source-derived summary

Cepentil, or Tsepentil, also known as N-cyclopentyllysergamide (NCPe-LA) or as lysergic acid cyclopentylamide (LCyP), is an analogue of LSD developed in the former Soviet Union which acts as an antagonist at serotonin receptors. It does not produce hallucinogen-like effects in animal studies, instead being described as an "energizer" by contemporary sources, suggesting an action similar to the antidementia drug hydergine, however the pharmacology of cepentil has not been studied with modern techniques.

Editorial summary

“Cepentil” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what Cepentil, pharmaceutical and compound can confirm, complicate or overturn.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current 72-word lead offers orientation but no explicit four-digit date, so chronology should not be assumed. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Cepentil, pharmaceutical and compound.
Editorial analysis

Why this record matters

“Cepentil” is worth following because a concise public description often conceals a longer documentary argument. Here, Cepentil, pharmaceutical and compound provides the most credible route into that argument.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Feb 12, 2026. The linked authority identifier is Q132069102. None of the 0 selected statements returned an explicit reference.

Critical limits

A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Cepentil”, its source revision and the description used here.
  2. Expand the search: follow Cepentil primary sources, Cepentil archive and Cepentil research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Cepentil”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Cepentil” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.